Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.

ABSTRACT:

Aims

In heart failure with reduced ejection fraction (HFrEF), there is an 'obesity paradox', where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium-glucose co-transporter 2 inhibitor according to baseline BMI in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF).

Methods and results

Body mass index was examined using standard categories, i.e. underweight (<18.5 kg/m² ); normal weight (18.5-24.9 kg/m² ); overweight (25.0-29.9 kg/m² ); obesity class I (30.0-34.9 kg/m² ); obesity class II (35.0-39.9 kg/m² ); and obesity class III (≥40 kg/m² ). The primary outcome in DAPA-HF wa

SUBMITTER: Adamson C 

PROVIDER: S-EPMC9292627 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature